These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 15134039

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes.
    Bacopoulou F, Markantonis SL, Pavlou E, Adamidou M.
    J Crit Care; 2003 Jun; 18(2):107-13. PubMed ID: 12800120
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
    Zobell JT, Stockmann C, Young DC, Cash J, McDowell BJ, Korgenski K, Sherwin CM, Spigarelli M, Chatfield BA, Ampofo K.
    Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
    [Abstract] [Full Text] [Related]

  • 9. Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin.
    Halacova M, Kotaska K, Kukacka J, Vavrova V, Kuzelova M, Ticha J, Prusa R.
    J Clin Pharm Ther; 2008 Aug; 33(4):409-17. PubMed ID: 18613859
    [Abstract] [Full Text] [Related]

  • 10. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
    Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP.
    J Clin Pharmacol; 2003 Oct; 43(10):1116-23. PubMed ID: 14517194
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF, Bulitta J, Lipman J, Kirkpatrick CM.
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis.
    Massie J, Cranswick N.
    J Paediatr Child Health; 2006 Oct; 42(10):601-5. PubMed ID: 16972966
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis].
    Canis F, Trivier D, Vic P, Ategbo S, Turck D, Husson MO.
    Pathol Biol (Paris); 1998 Jun; 46(6):449-51. PubMed ID: 9769880
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients.
    Lam W, Tjon J, Seto W, Dekker A, Wong C, Atenafu E, Bitnun A, Waters V, Yau Y, Solomon M, Ratjen F.
    J Antimicrob Chemother; 2007 Jun; 59(6):1135-40. PubMed ID: 17446242
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.